635 related articles for article (PubMed ID: 23170914)
41. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
Whalen K; Miller S; Onge ES
Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
[TBL] [Abstract][Full Text] [Related]
42. SGLT2 inhibition with dapagliflozin -- a novel approach for the management of type 2 diabetes.
Kilov G; Leow S; Thomas M
Aust Fam Physician; 2013 Oct; 42(10):706-10. PubMed ID: 24130972
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial.
Dharmalingam M; Aravind SR; Thacker H; Paramesh S; Mohan B; Chawla M; Asirvatham A; Goyal R; Shembalkar J; Balamurugan R; Kadam P; Alva H; Kodgule R; Tandon M; Vaidyanathan S; Pendse A; Gaikwad R; Katare S; Suryawanshi S; Barkate H
Drugs; 2020 Apr; 80(6):587-600. PubMed ID: 32162274
[TBL] [Abstract][Full Text] [Related]
44. [Dapagliflozin (forxiga®) : SGLT 2 cotransporter inhibitor as glucose-lowering agent in type 2 diabetes].
Scheen AJ
Rev Med Liege; 2016 Oct; 71(10):463-469. PubMed ID: 28383856
[TBL] [Abstract][Full Text] [Related]
45. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
Ku EJ; Lee DH; Jeon HJ; Oh TK
Diabetes Res Clin Pract; 2019 May; 151():65-73. PubMed ID: 30954510
[TBL] [Abstract][Full Text] [Related]
46. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus.
Plosker GL
Drugs; 2014 May; 74(7):807-24. PubMed ID: 24831734
[TBL] [Abstract][Full Text] [Related]
47. Dapagliflozin: A Review in Type 2 Diabetes.
Dhillon S
Drugs; 2019 Jul; 79(10):1135-1146. PubMed ID: 31236801
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
BMC Health Serv Res; 2015 Nov; 15():496. PubMed ID: 26541516
[TBL] [Abstract][Full Text] [Related]
49. Dapagliflozin for the treatment of type 2 diabetes.
Anderson SL; Marrs JC
Ann Pharmacother; 2012 Apr; 46(4):590-8. PubMed ID: 22433611
[TBL] [Abstract][Full Text] [Related]
50. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
Diabet Med; 2015 Jul; 32(7):890-8. PubMed ID: 25817050
[TBL] [Abstract][Full Text] [Related]
51. Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.
Ptaszynska A; Johnsson KM; Parikh SJ; de Bruin TW; Apanovitch AM; List JF
Drug Saf; 2014 Oct; 37(10):815-29. PubMed ID: 25096959
[TBL] [Abstract][Full Text] [Related]
52. Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial.
Henry RR; Strange P; Zhou R; Pettus J; Shi L; Zhuplatov SB; Mansfield T; Klein D; Katz A
Diabetes Technol Ther; 2018 Nov; 20(11):715-724. PubMed ID: 30222367
[TBL] [Abstract][Full Text] [Related]
53. Dapagliflozin combination therapy in type 2 diabetes mellitus.
Yacoub T
Postgrad Med; 2016 Jan; 128(1):124-36. PubMed ID: 26571022
[TBL] [Abstract][Full Text] [Related]
54. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.
Kasichayanula S; Liu X; Shyu WC; Zhang W; Pfister M; Griffen SC; Li T; LaCreta FP; Boulton DW
Diabetes Obes Metab; 2011 Jan; 13(1):47-54. PubMed ID: 21114603
[TBL] [Abstract][Full Text] [Related]
55. Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes.
Rosenstock J; Perl S; Johnsson E; García-Sánchez R; Jacob S
Diabetes Obes Metab; 2019 Sep; 21(9):2152-2162. PubMed ID: 31144431
[TBL] [Abstract][Full Text] [Related]
56. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
Matthaei S; Bowering K; Rohwedder K; Grohl A; Parikh S;
Diabetes Care; 2015 Mar; 38(3):365-72. PubMed ID: 25592197
[TBL] [Abstract][Full Text] [Related]
57. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC;
Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415
[TBL] [Abstract][Full Text] [Related]
58. Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial.
Yang W; Ma J; Li Y; Li Y; Zhou Z; Kim JH; Zhao J; Ptaszynska A
J Diabetes; 2018 Jul; 10(7):589-599. PubMed ID: 29215189
[TBL] [Abstract][Full Text] [Related]
59. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
Lambers Heerspink HJ; de Zeeuw D; Wie L; Leslie B; List J
Diabetes Obes Metab; 2013 Sep; 15(9):853-62. PubMed ID: 23668478
[TBL] [Abstract][Full Text] [Related]
60. Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease.
Leiter LA; Cefalu WT; de Bruin TW; Xu J; Parikh S; Johnsson E; Gause-Nilsson I
Diabetes Obes Metab; 2016 Aug; 18(8):766-74. PubMed ID: 27009868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
